GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘Gozo should market itself as a slow-life destination’ – GTA CEO Joe Muscat
He warned Gozo risks losing its competitive edge if it seeks to emulate mainland Malta.
Corinthia names Peter Roth as its first President of Hotel Operations
Peter Roth was recently Regional Vice President for the Emirati luxury hotel chain Jumeirah.
Michael Farrugia officially assumes role as Farsons CEO
'It is a privilege to be entrusted with the leadership of Farsons at such an important moment in its history,' ...
How Eunoia became Malta’s first locally registered Analytics on Microsoft Azure Specialisation partner
'It's heartbreaking to see companies making the wrong decisions,' says Eunoia Founder Stefan Farrugia.
